Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 6/20 | 0.96 |
| ▸ | GLA known ✓ | P06280 | 5/20 | 0.96 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.62 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.62 |
| ▸ | SRC known ✓ | P12931 | 1/20 | 0.57 |
| ▸ | CA2 known ✓ | P00918 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.96 |
| ▸ | HPGD | P15428 | 7/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.96 |
| ▸ | CA9 | Q16790 | 7/20 | 0.96 |
| ▸ | CA12 | O43570 | 5/20 | 0.96 |
| ▸ | CA1 | P00915 | 5/20 | 0.96 |
| ▸ | CASP1 | P29466 | 4/20 | 0.96 |
| ▸ | CASP7 | P55210 | 4/20 | 0.96 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.62 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30762676 | 1.00 | ALDH1A1 (0.96) | ALDH1A1KDM4EHPGDHSD17B10CA9 | |
| Hydrochloric Acid SCHEMBL2545954 | 1.00 | ALDH1A1 (0.96) | ALDH1A1KDM4EHPGDHSD17B10CA9 | |
| SCHEMBL29645144 | 0.98 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDHSD17B10CA9 | |
| SCHEMBL37677 | 0.98 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDHSD17B10CA9 | |
| SCHEMBL28806970 | 0.98 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDHSD17B10CA9 | |
| SCHEMBL1037558 | 0.96 | ALDH1A1 (0.96) | ALDH1A1KDM4EHPGDHSD17B10CA9 | |
| Bromide SCHEMBL18007249 | 0.96 | ALDH1A1 (0.96) | ALDH1A1KDM4EHPGDHSD17B10CA9 | |
| Bromide SCHEMBL30457821 | 0.96 | ALDH1A1 (0.96) | ALDH1A1KDM4EHPGDHSD17B10CA9 | |
| Bromide SCHEMBL28878217 | 0.95 | ALDH1A1 (0.93) | ALDH1A1KDM4EHPGDHSD17B10CA9 | |
| Acetic Acid SCHEMBL3998167 | 0.90 | ALDH1A1 (0.84) | ALDH1A1KDM4EHPGDHSD17B10CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364158-A1 | METHODS AND MATERIALS FOR TREATING GASTROINTESTINAL DISORDERS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2023-11-16 | — | — | US | disclosed |
| CN-117043157-A | ERAP inhibitors | 里尔大学 | 2023-11-10 | — | — | CN | disclosed |
| CN-113846115-B | Recombinant protein of house dust mite I allergen pro-Der p1, and preparation method and application thereof | 广州医科大学 | 2023-10-17 | — | — | CN | disclosed |
| US-20230313261-A1 | Biological Indicator Comprising Genetically-Modified Test Microorganism | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2023-10-05 | — | — | US | disclosed |
| CN-116672342-A | Application of berberine compound in preparation of drug of plasma kallikrein inhibitor | 上海泰楚生物技术有限公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-116672342-A | Application of berberine compound in preparation of drug of plasma kallikrein inhibitor | 上海泰楚生物技术有限公司 | 2023-09-01 | — | — | CN | disclosed |
| US-20230193347-A1 | Biological Indicator with Test Microorganisms Enveloped by Wax Composition | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2023-06-22 | — | — | US | disclosed |
| US-20230110772-A1 | Immobilized pH Indicator for Biological Indicator Growth Indication | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2023-04-13 | — | — | US | disclosed |
| US-20230047207-A1 | Self-Contained Biological Indicator with Salt Compound | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2023-02-16 | — | — | US | disclosed |
| WO-2021214595-A1 | BIOLOGICAL INDICATOR WITH TEST MICROORGANISMS ENVELOPED BY WAX COMPOSITION | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2021-10-28 | — | — | WO | disclosed |
| CN-106852146-A | Cell penetrating peptides and methods of making and using the same | 塞克洛波特斯公司 | 2017-06-13 | — | — | CN | disclosed |
| US-9266872-B2 | 2-hydroxyarylamide derivative or pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition for preventing or treating cancer containing same as active ingredient | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2016-02-23 | — | — | US | disclosed |
| EP-2873420-A1 | Bile acids and biguanides as protease inhibitors for preserving the integrity of peptides in the gut | Axcess Limited (GB) | 2015-05-20 | — | — | EP | disclosed |
| EP-2361091-B1 | BILE ACIDS AND BIGUANIDES AS PROTEASE INHIBITORS FOR PRESERVING THE INTEGRITY OF PEPTIDES IN THE GUT | AXCESS LTD (GB) | 2015-01-21 | — | — | EP | disclosed |
| US-20140221411-A1 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2014-08-07 | — | — | US | disclosed |
| US-20120035116-A1 | BILE ACIDS AND BIGUANIDES AS PROTEASE INHIBITORS FOR PRESERVING THE INTEGRITY OF PEPTIDES IN THE GUT | AXCESS LIMITED (GB) | 2012-02-09 | — | — | US | disclosed |
| EP-1511849-B1 | CONTINUOUS-FLOW ENZYME ASSAY WITH MASS SPECTROMETRY DETECTION | KIADIS B V (NL) | 2006-08-23 | — | — | EP | disclosed |
| US-20050239152-A1 | Continuous-flow enzyme assay | KIADIS B.V. (NL) | 2005-10-27 | — | — | US | disclosed |
| EP-1511849-A2 | CONTINUOUS-FLOW ENZYME ASSAY WITH MASS SPECTROMETRY DETECTION | Kiadis B.V. (NL) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003102222-A2 | CONTINUOUS-FLOW ENZYME ASSAY WITH MASS SPECTROMETRY DETECTION | KIADIS B.V. (NL) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035116-A1 | BILE ACIDS AND BIGUANIDES AS PROTEASE INHIBITORS FOR PRESERVING THE INTEGRITY OF PEPTIDES IN THE GUT | VIP, SI, SLC10A2 | GAA 76/4885GLA 192/4885MAOB 2763/4885 |
| US-20140221411-A1 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | TMPRSS2, TMPRSS4, PRSS2 | GAA 1428/4885GLA 1212/4885MAOB 1852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.